Flash Sale 70% Off
Give customers details about the banner image(s) or content on the template.
Science Library
Acidic cannabinoids are the naturally occurring “raw” forms of cannabinoids found in the plant—like THCA, CBDA, and CBGA. When heat is applied, they convert into more familiar cannabinoids (THC, CBD, CBG) through a process called decarboxylation. This guide explains the science in plain English, so you can interpret lab reports, understand “raw” extracts, and make smarter formulation choices.
Acidic cannabinoids (also called cannabinoid acids) are the original forms of cannabinoids produced by the plant. In the living plant, cannabinoids typically contain an extra chemical group called a carboxyl group (often shown as -COOH). That’s why they end with “A”: THCA, CBDA, CBGA.
Over time—or more quickly with heat—these acidic cannabinoids can convert into their neutral (decarboxylated) forms: THCA → THC, CBDA → CBD, CBGA → CBG/CBC/THC-pathway cannabinoids (depending on plant enzymes and processing).
“Acidic” and “neutral” describes whether the cannabinoid still has that extra -COOH group attached. Heat removes it—changing the molecule and often changing how it behaves in formulations.
| Acidic form | Neutral form | What converts it? | Common context |
|---|---|---|---|
| THCA | THC | Heat (decarboxylation) | Raw flower, “non-decarbed” extracts |
| CBDA | CBD | Heat | Raw hemp, minimally processed extracts |
| CBGA | CBG / CBC (pathway-dependent) | Enzymes in plant + processing | “Mother cannabinoid” in biosynthesis |
| CBCA | CBC | Heat | Less common, still relevant in full-spectrum profiles |
Plain-English takeaway: If a product or lab report lists a lot of THCA or CBDA, that doesn’t automatically mean the same thing as THC or CBD. Heat changes the story.
Decarboxylation is the process that removes the extra -COOH group from an acidic cannabinoid. In practice, it usually happens with heat.
Raw plant material → (heat / time / light) → neutral cannabinoids
Example: THCA → (heat) → THC
Decarboxylation matters because it can change: how a compound interacts with receptors, how it behaves in formulations, and how “Total THC” is calculated on lab reports.
THCA (tetrahydrocannabinolic acid) is the naturally occurring precursor to THC in the plant. When heated, THCA decarboxylates into THC.
If you’re evaluating products, the key is not just “THC” on the label—it’s how the lab calculates Total THC (more on that below).
CBDA (cannabidiolic acid) is the precursor to CBD and is abundant in raw hemp. When heated, CBDA decarboxylates into CBD.
Acidic and neutral cannabinoids are related but not identical—so interpreting lab results accurately matters.
Many Certificates of Analysis (COAs) show both acidic and neutral cannabinoids. Regulators and labs often calculate “Total” values using a conversion factor, because the acid form loses mass when it decarboxylates.
Common COA calculations (approximate):
Total THC = THC + (THCA × 0.877)
Total CBD = CBD + (CBDA × 0.877)
Layman’s explanation: That 0.877 factor accounts for the mass of the carboxyl group that’s lost during decarboxylation. This is why a product with “low THC” but “high THCA” can still have a meaningful Total THC.
Legality depends on jurisdiction and how compliance is calculated. In U.S. hemp contexts, compliance often considers Total THC, which may include THCA converted by a factor (see above). Always verify third-party lab testing and local rules for your state.
This page is for educational purposes and is not legal advice.
Most drug tests screen for THC metabolites, not “THCA” itself. However, products with measurable THCA and/or THC may contribute to THC metabolite detection depending on dose, metabolism, and test sensitivity.
If drug testing is a concern, choose products with clear lab results and THC specifications, and consult a qualified professional.
Scientific interest in acidic cannabinoids has increased over the past decade, with researchers investigating how cannabinoid acids differ from their decarboxylated counterparts in receptor interactions, pharmacokinetics, and stability. Many findings are preclinical (cell-based or animal models), and human clinical data remains limited.
A 2013 paper in the British Journal of Pharmacology (Bolognini et al.) reported that CBDA interacts with the 5-HT1A serotonin receptor and may function as an agonist in laboratory models, with receptor activity distinct from CBD under certain conditions.
Preclinical pharmacokinetic work has compared CBDA and CBD, suggesting that structural differences between acidic and neutral cannabinoids can influence absorption and metabolism. Results vary by model and formulation, and more human research is needed.
Multiple studies across natural products and analytical chemistry literature examine cannabinoid stability and conversion under heat and light. This research informs best practices for preserving acidic cannabinoids during manufacturing, storage, and testing.
Important: Research on cannabinoids is evolving. Many studies are preclinical and may not translate directly to clinical outcomes. This content is educational and does not diagnose, treat, cure, or prevent any disease.
Now that you understand how acidic cannabinoids work, explore how we apply cannabinoid science across targeted product lines. (Replace these links with your live collection URLs.)
Related reading: Rare Cannabinoids